These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 34158264)

  • 1. Successful Rapid Oral Desensitization to Ibrutinib in a Patient With Severe Immediate Hypersensitivity Reaction.
    Tsilimidos G; Horisberger A; Ribi C; Cairoli A; Stalder G
    Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):e745-e747. PubMed ID: 34158264
    [No Abstract]   [Full Text] [Related]  

  • 2. Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis.
    Lauer EM; Waterhouse M; Braig M; Mutter J; Bleul S; Duque-Afonso J; Duyster J; Marks R; Reinacher PC; Prinz M; Illerhaus G; Finke J; Schorb E; Scherer F
    Br J Haematol; 2020 Jul; 190(2):e110-e114. PubMed ID: 32452526
    [No Abstract]   [Full Text] [Related]  

  • 3. A Case of Bing-Neel Syndrome Treated Successfully With Ibrutinib Monotherapy Following Intensive Chemoimmunotherapy.
    Carella M; Stefoni V; Broccoli A; Argnani L; Zinzani PL
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e817-e819. PubMed ID: 34281758
    [No Abstract]   [Full Text] [Related]  

  • 4. Ibrutinib in primary central nervous system diffuse large B-cell lymphoma.
    T Low J; B Peters K
    CNS Oncol; 2020 Mar; 9(1):CNS51. PubMed ID: 32141313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Mantle cell lymphoma with central nervous system relapse successfully treated with nasogastric-tube administration of ibrutinib].
    Okahashi N; Uchihara M; Hoshino E
    Rinsho Ketsueki; 2020; 61(10):1508-1510. PubMed ID: 33162449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Combination of ibrutinib and temozolomide for the treatment of newly diagnosed elderly primary central nervous system diffuse large B cell lymphoma: a case report].
    Wang L; Li X; He YZ
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):482. PubMed ID: 32654461
    [No Abstract]   [Full Text] [Related]  

  • 7. Central Nervous System Post-transplant Lymphoproliferative Disorder: Response to Ibrutinib.
    Kallam A; Hansen N; Bierman P
    Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e930-e933. PubMed ID: 32782203
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).
    Renaud L; Bossard JB; Carpentier B; Terriou L; Cambier N; Chanteau G; Escure G; Tilmont R; Barbieux S; Wemeau M; Hieulle J; Boyle EM; Morschhauser F
    Eur J Haematol; 2021 Sep; 107(3):370-373. PubMed ID: 34018260
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use.
    Chen F; Pang D; Guo H; Ou Q; Wu X; Jiang X; Wei X; Liu S; Huang L; Liang Z; Zhou D; Li W
    Cancer Med; 2020 Nov; 9(22):8676-8684. PubMed ID: 33068336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience.
    Lewis KL; Chin CK; Manos K; Casey J; Hamad N; Crawford J; Ho SJ; Issa S; Grigg A; Wood P; Gandhi MK; Do B; Nastoupil L; Hawkes EA; Cheah CY
    Br J Haematol; 2021 Mar; 192(6):1049-1053. PubMed ID: 32677095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful ibrutinib treatment for central nervous system relapse of chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation.
    Tanigawa T; Sakurai M; Kato J; Mizuno K; Fujita S; Koda Y; Kikuchi T; Shimizu T; Okamoto S; Kataoka K
    Ann Hematol; 2022 Mar; 101(3):723-724. PubMed ID: 34235557
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy of ibrutinib as salvage treatment in a secondary central nervous system lymphoma (SCNSL) progressed after chemorefractory Primary Mediastinal B Cell Lymphoma (PMBCL).
    Malfona F; Testi AM; Moleti ML; Petrucci L; Leccisotti L; Martelli M; Di Rocco A
    Leuk Lymphoma; 2022 Feb; 63(2):483-486. PubMed ID: 34612154
    [No Abstract]   [Full Text] [Related]  

  • 13. B-cell prolymphocytic leukaemia with a t(4;14) FGFR3/IGH translocation: response to ibrutinib.
    George P; Brown A; Weinkove R
    Pathology; 2020 Jun; 52(4):491-492. PubMed ID: 32349864
    [No Abstract]   [Full Text] [Related]  

  • 14. Immediate reaction to ibrutinib amenable to oral desensitization.
    Phadke NA; Luk SO; Hochberg EP; Banerji A
    J Oncol Pharm Pract; 2021 Oct; 27(7):1802-1805. PubMed ID: 33793357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete Response of a Young Woman With MYD88
    Pabon CM; Neff JL; Forns TE; Wang J
    Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e809-e812. PubMed ID: 32660904
    [No Abstract]   [Full Text] [Related]  

  • 16. Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials.
    Morabito F; Tripepi G; Del Poeta G; Mauro FR; Reda G; Sportoletti P; Laurenti L; Coscia M; Herishanu Y; Bossio S; Varettoni M; Murru R; Chiarenza A; Visentin A; Condoluci A; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Al-Janazreh H; Vigna E; Martino EA; Cassin R; D Arrigo G; Galimberti S; Rago A; Angeletti I; Biagi A; Del Giudice I; Bomben R; Neri A; Fronza G; Monti P; Menichini P; Olivieri J; Cutrona G; Rossi D; Cuneo A; Di Raimondo F; Gaidano G; Polliack A; Trentin L; Foà R; Ferrarini M; Gattei V; Gentile M
    Am J Hematol; 2021 Aug; 96(8):E269-E272. PubMed ID: 33878220
    [No Abstract]   [Full Text] [Related]  

  • 17. CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.
    Kagiyama Y; Fujita S; Shima Y; Yamagata K; Katsumoto T; Nakagawa M; Honma D; Adachi N; Araki K; Kato A; Inaki K; Ono Y; Fukuhara S; Kobayashi Y; Tobinai K; Kitabayashi I
    Cancer Sci; 2021 Jun; 112(6):2314-2324. PubMed ID: 33792119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dramatic Efficacy of Ibrutinib in a Schnitzler Syndrome Case with Indolent Lymphoma.
    Claves F; Siest R; Lefebvre C; Valmary-Degano S; Carras S
    J Clin Immunol; 2021 Aug; 41(6):1380-1383. PubMed ID: 33871787
    [No Abstract]   [Full Text] [Related]  

  • 19. Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.
    Schaffer M; Chaturvedi S; Davis C; de Jong J; Aquino R; Oki Y; Fourneau N; Younes A; Balasubramanian S
    Cancer Treat Res Commun; 2020; 25():100235. PubMed ID: 33188997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma.
    Li J; Huang Y; Zhang Y; Wen J; Chen Y; Wang L; Jiang P; Hu J
    Med Oncol; 2021 Feb; 38(4):33. PubMed ID: 33629212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.